Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg−1) rFVIIa doses across clinical trials and registries-Reference-Cited by-同舟云学术

Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg−1) rFVIIa doses across clinical trials and registries

Published:2013-12-20 Issue:1 Volume:20 Page:e23-e31
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Shapiro A. D.¹,Neufeld E. J.²,Blanchette V.³,Salaj P.⁴,Gut R. Z.⁵,Cooper D. L.⁵

Affiliation:

1. Indiana Hemophilia and Thrombosis Center; Indianapolis IN USA

2. Division of Hematology/Oncology; Boston Children's Hospital; Boston MA USA

3. Department of Pediatrics, Hospital for Sick Children; Toronto Canada

4. Institute of Hematology and Blood Transfusion; Prague Czech Republic

5. Clinical Development and Medical Affairs - Biopharm, Novo Nordisk Inc.; Plainsboro NJ USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12329/fullpdf

Reference25 articles.

1. NovoSeven RT (Coagulation Factor VIIa [Recombinant], Room Temperature Stable) [prescribing information] Bagsvaerd, Denmark Novo Nordisk A/S 2010

2. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven);Kenet;J Thromb Haemost,2003

3. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors;Key;Thromb Haemost,1998

4. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison;Young;Haemophilia,2008

5. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial;Kavakli;Thromb Haemost,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors;Haemophilia;2021-10-11

2. Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A;Expert Opinion on Drug Safety;2021-02-27

3. The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors;Haemophilia;2019-09-05

4. Safety analysis ofrFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from theHAVENclinical program;Journal of Thrombosis and Haemostasis;2019-06-17

5. A promising on-demand treatment option for bleeding events in haemophilia patients with inhibitors;Haemophilia;2017-11